Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Abroad (travel likely)RecruitingPHASE1
Conditions
Sickle Cell Disease · Hb-SS Disease · Hemoglobin S · Disease Sickle Cell Anemia · Sickle Cell Disorders · Hemoglobin Beta Thalassemia Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Contact: Study coordinator (NIH Clinical Center Office of Patient Recruitment (OPR) · prpl@cc.nih.gov · 800-411-1222
Study leads
Swee Lay Thein, M.D.
Principal Investigator
National Heart, Lung, and Blood Institute (NHLBI)